M C Venier-Julienne
Overview
Explore the profile of M C Venier-Julienne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angotti C, Venier-Julienne M, Penna C, Femmino S, Sindji L, Paniagua C, et al.
Int J Pharm
. 2016 Nov;
523(2):506-514.
PMID: 27887883
Catestatin (CST), a fragment of Chromogranin-A, exerts angiogenic, arteriogenic, vasculogenic and cardioprotective effects. CST is a very promising agent for revascularization purposes, in "NOOPTION" patients. However, peptides have a very...
2.
Lacoeuille F, Hindre F, Venier-Julienne M, Sergent M, Bouchet F, Jouaneton S, et al.
Biomaterials
. 2011 Jul;
32(31):7999-8009.
PMID: 21788070
The aim of this work was to develop a new microparticulate system able to form a complex with radionuclides with a high yield of purity for diagnostic or therapeutic applications....
3.
Paillard-Giteau A, Tran V, Thomas O, Garric X, Coudane J, Marchal S, et al.
Eur J Pharm Biopharm
. 2010 Mar;
75(2):128-36.
PMID: 20226857
Incomplete protein release from PLGA-based microspheres due to protein interactions with the polymer is one of the main issues in the development of PLGA protein-loaded microspheres. In this study, a...
4.
Giteau A, Venier-Julienne M, Aubert-Pouessel A, Benoit J
Int J Pharm
. 2007 Dec;
350(1-2):14-26.
PMID: 18162341
One of the most challenging tasks in the delivery of therapeutic proteins from PLGA-based microparticles is the sustained and complete release of the protein in its native form. The mechanisms...
5.
Tatard V, Venier-Julienne M, Saulnier P, Prechter E, Benoit J, Menei P, et al.
Biomaterials
. 2004 Dec;
26(17):3727-37.
PMID: 15621263
To overcome certain problems encountered in cell therapy, particularly cell survival, lack of cell differentiation and integration in the host tissue, we developed pharmacologically active microcarriers (PAM). These biodegradable particles...
6.
Tatard V, Venier-Julienne M, Benoit J, Menei P, Montero-Menei C
Cell Transplant
. 2004 Nov;
13(5):573-83.
PMID: 15565869
Cell therapy will probably become a major therapeutic strategy in the coming years. Nevertheless, few cells survive transplantation when employed as a treatment for neuronal disorders. To address this problem,...
7.
Jarnet D, Denizot B, Hindre F, Venier-Julienne M, Lisbona A, Bardies M, et al.
Phys Med Biol
. 2004 May;
49(9):1803-15.
PMID: 15152932
To improve the performance of mono-extruded TLD threads as a dosimetric thermoluminescent tool (French Patent 9903729), a new process was developed by co-extrusion methodology leading to threads of 600 microm...
8.
Lemaire L, Roullin V, Franconi F, Venier-Julienne M, Menei P, Jallet P, et al.
NMR Biomed
. 2001 Oct;
14(6):360-6.
PMID: 11599034
The aim of this work was to assess the therapeutic efficacy of an intratumoral bolus injection of 5-fluorouracil (FU) compared to that of drug loaded in biodegradable microspheres, for the...
9.
Geze A, Venier-Julienne M, Cottin J, Faisant N, Benoit J
J Microencapsul
. 2001 Aug;
18(5):627-36.
PMID: 11508768
The aim of this study was to determine the bioburden of PLGA microspheres produced by the solvent emulsion/extraction process as a means of determining an appropriate gamma-irradiation dose for sterilization....
10.
Gouhier C, Chalon S, Venier-Julienne M, Bodard S, Benoit J, Besnard J, et al.
Neurosci Lett
. 2000 Jun;
288(1):71-5.
PMID: 10869818
Huntington's disease (HD) results from the degeneration of striatal neurones, mainly gamma-aminobutyric acid (GABA)ergic projection neurones and lately cholinergic interneurones. The use of trophic factors as agents able to prevent...